Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel plus Gemcitabine vs mFOLFIRINOX in Pancreatic Cancer
NCT04617821Phase 3Unknown
- Sponsor
- Fudan University
- Start
- Sep 2021
- Primary completion
- Sep 2024
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nab-paclitaxel and gemcitabine in pancreatic ductal adenocarcinoma (PDAC) (2 arms), sponsored by Fudan University. Primary endpoint: Overall Survival at 36 months. Status: unknown.
02
Drugs
nab-paclitaxelgemcitabine
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04617821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04617821.